SYRS YTD Return
Start date: 12/31/2021
End date: 12/01/2022
Start price/share: $32.60
End price/share: $3.95
Dividends collected/share: $0.00
SYRS YTD return: -87.88%
Annualized Gain: -95.75%
Starting investment: $10,000.00
Ending investment: $1,212.00
Years: 0.92


SYRS YTD return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare SYRS YTD return (see YTD Return Meaning) versus benchmarks:

YTD Return S&P
YTD Return Dow
YTD Return Nasdaq 100
YTD Return Russell 2000
YTD Return Gold
YTD Return 10 Year Treasury
YTD Return By Sector
YTD Return on $10,000.00
Without Dividends Reinvested Into SYRS


Also see: SYRS Average Annual Return
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients. The SYRS YTD return is shown above.

The YTD Return on the SYRS YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis.

Thus, researching Year-To-Date Returns is good practice for investors — whether SYRS YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the SYRS YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns.
Quotes delayed 20 minutes

Email EnvelopeFree SYRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in YTD Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Syros Pharmaceuticals (SYRS) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:

TALS YTD Return
TARA YTD Return
TARO YTD Return
TARS YTD Return
TBIO YTD Return
TCDA YTD Return
TCMD YTD Return
TCON YTD Return
TCRR YTD Return
TCRT YTD Return
More Healthcare companies »

 

SYRS YTD Return | www.YTDReturn.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in YTDReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.